康欣胶囊对血管性痴呆患者血浆同型半胱氨酸及β-淀粉样蛋白的影响

Effect of Kangxin Capsule on Homocysteine and β-amyloid Protein in Vascular Dementia Patients

目的 :观察康欣胶囊对血管性痴呆 (vasculardementia ,VD)患者血浆同型半胱氨酸 (homocys teine ,HCY)、β 淀粉样蛋白 (β amyloidprotein ,β Ap)的影响。 方法 :将VD患者 6 3例 ,随机分为治疗组 (33例 )和对照组 (30例 ) ,两组均给予基础治疗 ,治疗组加服康欣胶囊 ,对照组加服喜得镇。观察两组患者治疗前后血浆HCY、β Ap水平及简易智能量表 (minimentalstateexamination ,MMSE)、日常生活功能水平 (ac tivitiesofdailyliving ,ADL)量表、中医证候评分的变化。结果 :康欣胶囊能显著降低患者血浆HCY、β Ap水平 (P <0 0 1) ,提高MMSE评分 ,降低ADL评分 ,改善中医证候。结论 :康欣胶囊可有效调节VD患者血浆HCY、β Ap水平。

Objective: To observe the effect of Kangxin capsule (KXC) on homocysteine (HCY) and β-amyloid protein (β-Ap) in patients with vascular dementia. Methods: Sixty-three patients with vascular dementia were randomly divided into two groups, the 33 patients in the treated group and the 30 in the control group. Basal treatment were given to both groups, besides, KXC was given to the treated group and Hydergine was given to the control group. The levels of plasma HCY, β-Ap as well as the changes of mini mental state examination (MMSE), activity of daily living (ADL) and TCM Syndrome scoring were observed before and after treatment. Results: KXC could significantly decrease the levels of HCY and β-Ap (P<0 01), rise the MMSE scores, reduce ADL scores and ameliorate TCM Syndrome. Conclusion: KXC can effectively regulate the levels of HCY, β-Ap in vascular dementia patients.